作者：
Giles,F.J. [1]
;
Vey,N. [2]
;
Rizzieri,D. [3]
;
Ravandi,F. [4]
;
Prebet,T. [5]
;
Borthakur,G. ;
Jacobsen,T.F. ;
Hagen,S. ;
Nilsson,B. ;
O'Brien,S.
作者单位：
Clavis Pharma, Oslo, Norway
[1]
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States
[2]
Department of Hematology, Institut Paoli-Calmettes, Marseille, France
[3]
HRB Clinical Research Facilities, National University of Ireland, Galway and Trinity College Dublin
[4]
Division of Cellular Therapy, Duke University Hospital, Durham, NC, United States
[5]
发布时间
2013-11-20
换一批
